Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).

Trial Details

NCT ID
NCT06251947
Phase
PHASE2
Sponsor
Shandong University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Efbemalenograstim Alfa
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Jinan, Shandong, China|36.66833,116.99722
  • Qingdao, Shandong, China|36.06488,120.38042
  • Taiyuan, Shanxi, China|37.86944,112.56028

Key Eligibility Criteria

  • ≥ 18 years old and ≤ 70 years old.
  • First-line epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) and first-line treatment or recurrent/metastat…
  • Planned to receive 3-6 cycles of paclitaxel + carboplatin/cisplatin ± bevacizumab therapy.
  • Eastern Cooperative Oncology Group (ECOG) score \< 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →